Common use of Additional TCR Targets Clause in Contracts

Additional TCR Targets. GSK shall have the right to add up to [*] additional TCR Targets (other than any Excluded Target) believed to be useful in the Oncology Field as Collaboration Targets, each of which shall be deemed an “Additional Target,” subject to payment of [*] for each such Additional Target selected, within [*] of receipt of a valid invoice therefor from Lyell. Any such Additional Target for a TCR T-Cell Therapy must be selected by GSK prior to the end of the [*] by written notice thereof to Lyell specifically referencing this Section 3.3(c), together with a written description of such TCR Target and other items described in Exhibit 3.3(c) (“Target Selection Notice”).